Thiotepa
Primary Central Nervous System Lymphoma
Explore 71 assets in Primary Central Nervous System Lymphoma →Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Zhejiang Cancer Hospital
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07416890CT.gov Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma | — | Recruiting | — | — | — |
NCT07191431CT.gov A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA） | — | Recruiting | — | — | — |
NCT06901999CT.gov Methotrexate or Thiotepa Combined With R-CHOP and Orelabrutinib in CNSL Patients | — | Not Yet Recruiting | — | — | — |
NCT06832267CT.gov Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL | — | Recruiting | — | — | — |
NCT06646211CT.gov High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ) | — | Not Yet Recruiting | — | — | — |
NCT05931328CT.gov The Study of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma Patients. | — | Recruiting | — | — | — |
NCT07014943CT.gov High-Dose Gemcitabine, Busulfan, and Thiotepa Followed by ASCT in Primary Central Nervous System Lymphoma | — | Recruiting | — | — | — |
NCT05021770CT.gov Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma | — | Unknown | — | — | — |
NCT01011920CT.gov Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma | — | Completed | — | — | — |
NCT00863460CT.gov Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients | — | Unknown | — | — | — |
Show 1 more trialShow fewer
NCT00647049CT.gov Freiburg ZNS-NHL Study | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Primary Central Nervous System Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Thiotepa (this asset) | Zhejiang Cancer Hospital | P2 | B · 63 |
| Etoposide | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | P4 | BBB |
| (+)-Vincristine | Ono Pharmaceutical Co., Ltd. | P4 | BBB |
| Orelabrutinib | The First Affiliated Hospital with Nanjing Medical University | P3 | BB |
| Adriamycin | Juan P. Alderuccio, MD | P4 | BB |
| Idarubicin | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | P4 | BB |
| Cyclophosphamide | Juan P. Alderuccio, MD | P4 | BB |
| Cytarabine | The Lymphoma Academic Research Organisation | P4 | BB |
| Rituximab | Ono Pharmaceutical Co., Ltd. | P4 | BB |
+42 more in the Primary Central Nervous System Lymphoma cohort
Other indications for Thiotepa
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Graft Versus Host Disease | — | P4 | BBB · 73 |
| Myelodysplastic/Myeloproliferative Neoplasm | — | P2/3 | BBB · 72 |
| Juvenile Myelomonocytic Leukemia | — | P3 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- EtoposideFederal Research Institute of Pediatric Hematology, Oncology and ImmunologyBBB
- (+)-VincristineOno Pharmaceutical Co., Ltd.BBB
- OrelabrutinibThe First Affiliated Hospital with Nanjing Medical UniversityBB
- AdriamycinJuan P. Alderuccio, MDBB
- IdarubicinFederal Research Institute of Pediatric Hematology, Oncology and ImmunologyBB
Citation
Floatz Terminal. Thiotepa in Primary Central Nervous System Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/thiotepa-primary-central-nervous-system-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →